The publication highlights the ability of Cas-CLOVER to perform multiplexed gene editing to produce allogeneic products with a high percentage of TGCS cells that can lead to better tolerance and deeper clinical responses
Cas-CLOVER demonstrated lower off-target and translocation activity than other published technologies including CRISPR, TALEN, and base editors
SAN DIEGO, June 29, 2022 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company using proprietary genetic engineering platform technologies to create curable cell and gene therapies, today announced a peer-reviewed publication review highlighting the potential of its proprietary Cas-CLOVER site-specific gene-editing system as a high-throughput platform for allogeneic CAR-T cell production. The paper, titled “Cas-CLOVER is a novel high-fidelity nuclease for the safe and robust generation of TSCM– enriched allogeneic CAR-T cells“, was published online today in Molecular Therapy – Nucleic Acids. The document will appear in print in the September 2022 journal number.
Poseida announces a publication on the potential of Cas-CLOVER as a robust gene editing system in the development of #allogeneic CAR-T.
“We are excited to release data from this very comprehensive study of our gene editing system in T cells,” said Eric Ostertag, MD, Ph.D., Executive Chairman of Poseida Therapeutics. “This publication validates the accuracy of our proprietary Cas-CLOVER system, which is used in the manufacture of our fully allogeneic product candidates currently in clinical trials, including P-BCMA-ALLO1 for relapsed/refractory multiple myeloma and P -MUC1C-ALLO1 for multiple solid tumor indications.”
Cas-CLOVER is a new high-fidelity gene editing system that can be used for high-efficiency gene editing in T cells to create allogeneic CAR-T products. In these published studies, Cas-CLOVER was used for multiplexed gene editing in resting T cells, resulting in allogeneic product candidates with a high percentage (45%-70%) of stem cell memory T desirable (TGCS) cells. Using next-generation sequencing, off-target activity was measured at a rate between 0.012% and 0.089%, which is significantly lower than many other gene-editing platforms. Additionally, off-target translocations, which are unwanted chromosomal abnormalities, approached the lower limit of detection at a frequency of less than 0.01%.
“Cas-CLOVER is a highly versatile and precise system that can be used to perform site-specific deletions, insertions, and knock-ins and works in multiple cell types,” said Blair Madison, Ph.D., Vice President, Genetic Engineering at Poseida Therapeutics, first author of the publication. “We continue to innovate, including improving Cas-CLOVER, to create potentially transformative treatments for oncology and rare disease patients. »
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to using our proprietary genetic engineering platform technologies to create next-generation cell and gene therapies with the ability to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA delivery system, the specific gene editing system Cas-CLOVER site and nanoparticles and AAV-based gene delivery technologies. The technologies in our core platform are useful, alone or in combination, in numerous cell and gene therapeutic modalities and enable us to design our portfolio of product candidates designed to overcome key limitations of current generation cell and gene therapies. To learn more, visit www.poseida.com and join us on Twitter and LinkedIn.
Statements in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the benefits potentials of Poseida’s technology platforms and product candidates, the safety and efficacy of Poseida’s Cas-CLOVER site-specific gene editing system, Poseida’s plans and strategy with respect to the development of its technologies and product candidates, as well as anticipated timelines and milestones regarding Poseida Activities’ development programs and manufacturing. Because these statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements. These forward-looking statements are based on Poseida’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in these forward-looking statements due to various risks and uncertainties, which include, but are not limited to, risks and uncertainties associated with the development and regulatory approval of new product candidates in the biopharmaceutical industry and other risks described in Poseida’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Show original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-publication-highlighting-potential-of-cas-clover-as-an-efficient-and-robust-gene-editing-system-for- allogeneic-car-t-product-development-301578250.html
SOURCE Poseida Therapeutics, Inc.